USFDA classifies Cipla Goa facility as VAI
Mumbai: Through a recent BSE filing, Cipla has informed that the United States Food and Drug Administration (USFDA) has classified the routine current Good Manufacturing Practices (cGMP) inspection at the Company's manufacturing facility in Goa as Voluntary Action Indicated (VAI).
The inspection was held from 10th – 21st June, 2024.
Read also: Cipla UK arm inks pact to purchase 6.9124 percent stake in Cipla Jiangsu Pharma
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
Read also: Cipla, Alkem vie for Rs 4,000 crore stake in India's largest stent manufacturer: Report
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.